Are lung adenocarcinoma mutations shaping the immune microenvironment?
作者信息
Rochigneux Philippe, Garon Edward B
机构信息
Medical Oncology Department, Paoli-Calmettes Institute, 13009 Marseille, France.
Immunity & Cancer team, Inserm, U1068, Centre de Recherche en Cancérologie de Marseille, Paoli-Calmettes Institute, Aix-Marseille University, France.
出版信息
Transl Cancer Res. 2018 Aug;7(Suppl 7):S740-S742. doi: 10.21037/tcr.2018.07.17.
Abstract
摘要
相似文献
1
Are lung adenocarcinoma mutations shaping the immune microenvironment?肺腺癌突变是否正在塑造免疫微环境？
Transl Cancer Res. 2018 Aug;7(Suppl 7):S740-S742. doi: 10.21037/tcr.2018.07.17.
2
, and Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.KRAS 突变预测肺腺癌的肿瘤免疫特征和对 PD-1 抗体的反应。
Clin Cancer Res. 2018 Nov 15;24(22):5710-5723. doi: 10.1158/1078-0432.CCR-18-0163. Epub 2018 May 15.
3
Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma.- 突变与 PD-1 抑制剂耐药在 - 突变型肺腺癌中的研究进展
Cancer Discov. 2018 Jul;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099. Epub 2018 May 17.
4
Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.基于人群的非小细胞肺癌队列中的突变模式以及 KRAS 和 TP53 或 STK11 同时突变的预后影响。
Lung Cancer. 2019 Apr;130:50-58. doi: 10.1016/j.lungcan.2019.01.003. Epub 2019 Jan 9.
5
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.对具有完整注释临床随访的早期肺腺癌进行全外显子组测序和免疫分析。
Ann Oncol. 2017 Jan 1;28(1):75-82. doi: 10.1093/annonc/mdw436.
6
Impact of and Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With -Mutated Advanced Non-Small-Cell Lung Cancer.EGFR和其他共突变对EGFR突变型晚期非小细胞肺癌患者一线全身治疗后结局的影响。 （注：原文中“and”前后内容缺失，这里是补充完整后进行的翻译）
JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00326. Epub 2019 May 10.
7
Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.血浆游离 DNA 靶向测序预测晚期非小细胞肺癌对 PD1 抑制剂的反应。
Lung Cancer. 2019 Nov;137:1-6. doi: 10.1016/j.lungcan.2019.09.005. Epub 2019 Sep 6.
8
Potential Predictive Value of and Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.在肺腺癌中， 与 突变状态对 PD-1 阻断免疫治疗反应的潜在预测价值。
Clin Cancer Res. 2017 Jun 15;23(12):3012-3024. doi: 10.1158/1078-0432.CCR-16-2554. Epub 2016 Dec 30.
9
Intratumoral Immune Cell Densities Are Associated with Lung Adenocarcinoma Gene Alterations.肿瘤内免疫细胞密度与肺腺癌基因突变相关。
Am J Respir Crit Care Med. 2016 Dec 1;194(11):1403-1412. doi: 10.1164/rccm.201510-2031OC.
10
Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma.肺浸润前和早期浸润性腺癌的基因组景观和免疫微环境特征。
J Thorac Oncol. 2019 Nov;14(11):1912-1923. doi: 10.1016/j.jtho.2019.07.031. Epub 2019 Aug 22.
引用本文的文献
1
Construction of a prognostic model for lung adenocarcinoma based on bioinformatics analysis of metabolic genes.基于代谢基因生物信息学分析构建肺腺癌预后模型
Transl Cancer Res. 2020 May;9(5):3518-3538. doi: 10.21037/tcr-20-1571.
2
Hormone receptor expression correlates with EGFR gene mutation in lung cancer in patients with simultaneous primary breast cancer.激素受体表达与同时患有原发性乳腺癌的肺癌患者的EGFR基因突变相关。
Transl Lung Cancer Res. 2020 Apr;9(2):325-336. doi: 10.21037/tlcr-20-513.
本文引用的文献
1
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.一项评估帕博利珠单抗在 EGFR 突变、PD-L1 阳性、初治的晚期 NSCLC 患者中的疗效和安全性的 II 期临床研究。
J Thorac Oncol. 2018 Aug;13(8):1138-1145. doi: 10.1016/j.jtho.2018.03.035. Epub 2018 Jun 1.
2
Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma.- 突变与 PD-1 抑制剂耐药在 - 突变型肺腺癌中的研究进展
Cancer Discov. 2018 Jul;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099. Epub 2018 May 17.
3
, and Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.KRAS 突变预测肺腺癌的肿瘤免疫特征和对 PD-1 抗体的反应。
Clin Cancer Res. 2018 Nov 15;24(22):5710-5723. doi: 10.1158/1078-0432.CCR-18-0163. Epub 2018 May 15.
4
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.纳武利尤单抗联合伊匹单抗治疗高肿瘤突变负荷肺癌。
N Engl J Med. 2018 May 31;378(22):2093-2104. doi: 10.1056/NEJMoa1801946. Epub 2018 Apr 16.
5
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.肺免疫预后指数与晚期非小细胞肺癌患者免疫检查点抑制剂疗效的相关性。
JAMA Oncol. 2018 Mar 1;4(3):351-357. doi: 10.1001/jamaoncol.2017.4771.
6
High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy.高维单细胞分析预测抗 PD-1 免疫治疗反应。
Nat Med. 2018 Feb;24(2):144-153. doi: 10.1038/nm.4466. Epub 2018 Jan 8.
7
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.T细胞活力与肿瘤负荷之比与抗PD-1反应相关。
Nature. 2017 May 4;545(7652):60-65. doi: 10.1038/nature22079. Epub 2017 Apr 10.
8
Potential Predictive Value of and Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.在肺腺癌中， 与 突变状态对 PD-1 阻断免疫治疗反应的潜在预测价值。
Clin Cancer Res. 2017 Jun 15;23(12):3012-3024. doi: 10.1158/1078-0432.CCR-16-2554. Epub 2016 Dec 30.
9
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.由JAK1/2突变介导的对PD-1阻断的原发性耐药
Cancer Discov. 2017 Feb;7(2):188-201. doi: 10.1158/2159-8290.CD-16-1223. Epub 2016 Nov 30.
10
Lung Cancer Subtypes Generate Unique Immune Responses.肺癌亚型产生独特的免疫反应。
J Immunol. 2016 Dec 1;197(11):4493-4503. doi: 10.4049/jimmunol.1600576. Epub 2016 Oct 31.
Zotero 插件